Among multiple cancers, high expression of RGS19 showed a particularly strong impact on BLCA, because both OS and DFS were significantly lower in BLCA patients with high RGS19 expression than in those with low RGS19 expression. This evidence concerns the gene RGS19 and bladder transitional cell carcinoma.